OPEN PEER REVIEW

Open Peer Review (OPR)

As a new feature for progressing towards transparency, we decided to open a new window for all of our editors as well as authors titled "**Open Peer Review**". We hope by this new facility, our reviewers will be more motivated and authors will be more satisfied with the review process. We believe that publishing our peer review reports could make a transparent and clear environment for all our efforts within a journal, but not all reviewers tend to publish their comments.

What is "Open Peer Review" process?

An "Open Peer Review" process is making the details of all review process (including reviewers, associate editors, and EICs comments) as "Public" as it is agreed by EIC, Authors, and reviewers.

Advantages of "Open Peer Review" process

- More transparency, constructiveness and tactful comments of the peer review process: leads to an increase in the quality of reviews
- More motivations for all involved roles in the review process
- Authors' satisfactions from the review process: Increases honesty between authors and reviewers
- Education of both authors and new students
- Prevents reviewers from following their individual agendas and leading to the detection of reviewers' conflicts of interests

You can find out more at:
https://brief.land/briefland/knowledgebase/category/tree.html#opr.html

Shiraz E-Medical Journal
Article DOI: 10.5812/semj.104239
Published in: Shiraz E-Medical Journal: 22(6); e104239

Peer Review Report for "A Double-blind Randomized Controlled Trial on the Effects of Montelukast on the Serum Level of Inflammatory Factors in Patients with Chronic Obstructive Pulmonary Disease"

Author(s): Alireza Azargoon, Ali Kharazmkia, Nazanin Kordalivand, Mehdi Birjandi, Samareh Mir

Review Timeline:

Submit Date: 9 Jun 2020
Revised Date: 14 Jul 2020
Accepted Date: 17 Jul 2020

Revision (0)

Here, you can see the **Reviewers**, **Associate Editors** and **EICs'** comments from the beginning to the end of the revision process.

REFEREE: Associate Editor | **Revision** (0) 11 Jul 2020

Dear EIC,
- Regarding the article examining the effect of Monte Lucast tablets on inflammatory factors in COPD patients, it should be explained in the article why it is thought that Monte Lucast can reduce inflammatory factors and what is the basis of this theory?
- The mechanism of Montelukast is to inhibit the interleukin receptor so that the interleukin does not work and stimulates the effector cells, and the secretion of inflammatory factors is not done in such a way that Montelukast is thought to be able to reduce these factors. Although studies have been conducted on this issue, which is also mentioned in the article, this issue should also be mentioned.
Thanks.

REFEREE: EIC | **Revision (0)** 12 Jul 2020

Dear Authors,

- There should be an explanation of the logic of the study and its novelty.
- The figure is of low quality.

Thanks.

OPEN PEER REVIEW

Revision (1)

Reply to Reviewers

Ideally, the reviewing process can significantly improve the submitted manuscripts by allowing the authors to take into account the advice of reviewers. Author(s) must reply to all reviewers' comments in a separate Word file, point by point. A "**Reply to Reviewers**" document is submitted along with revised manuscript during submission of revised files, summarizing the changes that the authors made in response to the reviewers' comments. The responses to reviewers' comments specifies how the authors addressed each comment the reviewers made.

You can read the authors' responses to the reviewers' comments in the next page.

Dear Editor,

We would like to thank you for the letter dated 07/12/2020, and the opportunity to resubmit a revised copy of this manuscript. We would also like to take this opportunity to express our thanks to the reviewers for the positive feedback and helpful comments for correction or modification.

We believe have resulted in an improved revised manuscript, which you will find uploaded alongside this document. The manuscript has been revised to address the reviewer comments, which are appended alongside our responses to this letter.

We very much hope the revised manuscript is accepted for publication in Shiraz E-Medical Journal.

Sincerely yours,

Dr. Ali Kharazmkia

on behalf of the authors

Associate Editor 1:	*Response:*
Regarding the article examining the effect of Monte Lucast tablets on inflammatory factors in COPD patients, it should be explained in the article why it is thought that Monte Lucast can reduce inflammatory factors and what is the basis of this theory? The mechanism of Montelukast is to inhibit the interleukin receptor so that the interleukin does not work and stimulates the effector cells, and the secretion of inflammatory factors is not done in such a way that Montelukast is thought to be able to reduce these factors. Although studies have been conducted on this issue, which are also mentioned in the article, this issue should also be mentioned.	The text of the article was corrected as follows: "However, the mechanism of Montelukast is to inhibit the interleukin receptor to impair the function of interleukin and inhibit the stimulation of effective cells and the secretion of inflammatory factors, On the other hand Montelukast has been shown to inhibit several proinflammatory cytokins in animal models of asthma. Maeba et al. reported an inhibitory effect of montelukast on the lipopolysaccharide induced production of IL-1β, IL-6, TNF-α and MCP-1 from peripheral blood mononuclear cells, while Can et al. demonstrated a decrease in serum TNF-α levels in pediatric asthmatics with montelukast treatment."

EIC Decision:

There should be explanation of the logic of study and its novelty .	The text of the article was corrected as follows: "Considering that previous studies on some of the beneficial and anti-inflammatory effects of Monte Lukast have been shown in COPD animal models; Despite the fact that the results are unknown or less worked in human studies, due to the known pathogenesis of COPD and the mechanism of action of Montelukast and its effectiveness in asthmatic patients, as well as its availability and cheapness, and above all the effect of inflammatory factors in the progression of the COPD disease,"
Figure is of low quality.	Corrected.

OPEN PEER REVIEW

Revision (1)

Here, you can see the **Reviewers**, **Associate Editors** and **EICs'** comments from the beginning to the end of the revision process.

REFEREE: EIC | **Revision (1)** 17 Jul 2020

Dear Author,
The document is reviewed carefully by the reviewers. According to their comments and your revisions as requested, this manuscript is accepted.
Thanks.